Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $17.25.

Several equities analysts have recently issued reports on ENTA shares. HC Wainwright decreased their price objective on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, December 24th. JMP Securities reiterated a “market outperform” rating and issued a $21.00 target price (down from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. Finally, Robert W. Baird dropped their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 26th.

Insider Activity

In other news, CEO Jay R. Luly sold 5,142 shares of the business’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $8.06, for a total transaction of $41,444.52. Following the transaction, the chief executive officer now owns 801,638 shares of the company’s stock, valued at approximately $6,461,202.28. The trade was a 0.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 13.64% of the company’s stock.

Institutional Trading of Enanta Pharmaceuticals

Several hedge funds have recently made changes to their positions in ENTA. US Bancorp DE lifted its stake in Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 4,243 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Enanta Pharmaceuticals in the third quarter valued at $122,000. Quest Partners LLC grew its stake in Enanta Pharmaceuticals by 65.0% during the 3rd quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 7,535 shares in the last quarter. Valence8 US LP purchased a new stake in Enanta Pharmaceuticals during the 3rd quarter worth about $207,000. Finally, Barclays PLC raised its position in Enanta Pharmaceuticals by 294.2% in the 3rd quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock valued at $285,000 after purchasing an additional 20,478 shares in the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Price Performance

Shares of ENTA stock opened at $5.25 on Monday. The business has a fifty day moving average of $7.23 and a 200 day moving average of $10.70. Enanta Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $17.80. The firm has a market capitalization of $111.25 million, a price-to-earnings ratio of -0.96 and a beta of 0.56.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The firm had revenue of $14.60 million during the quarter, compared to analysts’ expectations of $17.99 million. During the same quarter in the previous year, the business earned ($1.33) earnings per share. The company’s revenue for the quarter was down 22.8% compared to the same quarter last year. As a group, equities research analysts expect that Enanta Pharmaceuticals will post -4.93 earnings per share for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.